新型治疗分化型甲状腺癌的药物。
Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
机构信息
Department of Metabolism, Endocrinology and Diabetes, University of Michigan, Lobby C #1300, 4029 Avenue Maria Drive, Ann Arbor, MI 48105, USA.
Department of Hematology and Oncology, University of Michigan, 1500 East Medical Center Drive Med Inn Building, Room C369, Ann Arbor, MI 48109, USA.
出版信息
Endocrinol Metab Clin North Am. 2022 Jun;51(2):367-378. doi: 10.1016/j.ecl.2021.11.019. Epub 2022 May 4.
The current treatments for radioactive iodine (RAI) -refractory differentiated thyroid cancer (DTC) are evolving as cancer genomics are further understood. Multitargeted tyrosine kinase inhibitors are the first-line therapy for symptomatic or progressive disease; however, considerable adverse effects have spurred the development of targeted therapies for redifferentiation of iodine avidity and the treatment of RAI-refractory DTC. Next-generation sequencing allows for the use of tumor-targeted therapeutics, such as MEK1/2, BRAF, RET, and NTRK inhibitors. Immunotherapy is also under investigation as a therapeutic option for this disease.
随着癌症基因组学的进一步研究，放射性碘（RAI）难治性分化型甲状腺癌（DTC）的当前治疗方法正在不断发展。多靶点酪氨酸激酶抑制剂是有症状或进展性疾病的一线治疗药物；然而，相当大的不良反应促使人们开发了针对碘摄取能力再分化和 RAI 难治性 DTC 的靶向治疗方法。下一代测序可用于肿瘤靶向治疗，如 MEK1/2、BRAF、RET 和 NTRK 抑制剂。免疫疗法也作为该疾病的一种治疗选择正在进行研究。
Zotero 插件